Michael K Wendt

List of Publications by Year in Descending Order

42 papers	2,003 citations	23 h-index	44 g-index
46 ext. papers	2,410 ext. citations	6.8 avg, IF	5.22 L-index

#	Paper	IF	Citations
42	Increased Ammonium Toxicity in Response to Exogenous Glutamine in Metastatic Breast Cancer Cells. *Metabolites*, **2022**, 12, 469	5.6	
41	Pyruvate carboxylase and cancer progression. *Cancer & Metabolism*, **2021**, 9, 20	5.4	7
40	Epigenetic targeting of neuropilin-1 prevents bypass signaling in drug-resistant breast cancer. *Oncogene*, **2021**, 40, 322-333	9.2	11
39	High-Throughput Magnetic Actuation Platform for Evaluating the Effect of Mechanical Force on 3D Tumor Microenvironment. *Advanced Functional Materials*, **2021**, 31,	15.6	4
38	Fibroblast growth factor receptor facilitates recurrence of minimal residual disease following trastuzumab emtansine therapy. *Npj Breast Cancer*, **2021**, 7, 5	7.8	4
37	Optimization and Anti-Cancer Properties of Fluoromethylketones as Covalent Inhibitors for Ubiquitin C-Terminal Hydrolase L1. *Molecules*, **2021**, 26,	4.8	1
36	The Dynamic Relationship of Breast Cancer Cells and Fibroblasts in Fibronectin Accumulation at Primary and Metastatic Tumor Sites. *Cancers*, **2020**, 12,	6.6	51
35	Transglutaminase-2 facilitates extracellular vesicle-mediated establishment of the metastatic niche. *Oncogenesis*, **2020**, 9, 16	6.6	61
34	SHP2 is a multifunctional therapeutic target in drug resistant metastatic breast cancer. *Oncogene*, **2020**, 39, 7166-7180	9.2	18
33	Fibronectin-Expressing Mesenchymal Tumor Cells Promote Breast Cancer Metastasis. *Cancers*, **2020** , 12,	6.6	9
32	Ubiquitin C-Terminal Hydrolase L1: Biochemical and Cellular Characterization of a Covalent Cyanopyrrolidine-Based Inhibitor. *ChemBioChem*, **2020**, 21, 712-722	3.8	16
31	PBRM1 Regulates Stress Response in Epithelial Cells. *IScience*, **2019**, 15, 196-210	6.1	8
30	Spleen Tyrosine Kinase-Mediated Autophagy Is Required for Epithelial-Mesenchymal Plasticity and Metastasis in Breast Cancer. *Cancer Research*, **2019**, 79, 1831-1843	10.1	70
29	Hyaluronic acid, CD44 and RHAMM regulate myoblast behavior during embryogenesis. *Matrix Biology*, **2019**, 78-79, 236-254	11.4	18
28	Application of a Substrate-Mediated Selection with c-Src Tyrosine Kinase to a DNA-Encoded Chemical Library. *Molecules*, **2019**, 24,	4.8	10
27	Selection of DNA-Encoded Libraries to Protein Targets within and on Living Cells. *Journal of the American Chemical Society*, **2019**, 141, 17057-17061	16.4	51
26	Analytical Pipeline for Discovery and Verification of Glycoproteins from Plasma-Derived Extracellular Vesicles as Breast Cancer Biomarkers. *Analytical Chemistry*, **2018**, 90, 6307-6313	7.8	35

25	Pyruvate carboxylase supports the pulmonary tropism of metastatic breast cancer. *Breast Cancer Research*, **2018**, 20, 76	8.3	51
24	Biased signaling downstream of epidermal growth factor receptor regulates proliferative versus apoptotic response to ligand. *Cell Death and Disease*, **2018**, 9, 976	9.8	11
23	Autocrine Fibronectin Inhibits Breast Cancer Metastasis. *Molecular Cancer Research*, **2018**, 16, 1579-1589	6.6	70
22	The paradoxical functions of EGFR during breast cancer progression. *Signal Transduction and Targeted Therapy*, **2017**, 2,	21	57
21	Phosphoproteins in extracellular vesicles as candidate markers for breast cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 3175-3180	11.5	201
20	Selective Inhibition of STAT3 Phosphorylation Using a Nuclear-Targeted Kinase Inhibitor. *ACS Chemical Biology*, **2017**, 12, 2371-2378	4.9	11
19	Regulation of epithelial-mesenchymal transition and metastasis by TGF-P-bodies, and autophagy. *Oncotarget*, **2017**, 8, 103302-103314	3.3	56
18	Targeting FGFR for the Treatment of Breast Cancer. *Resistance To Targeted Anti-cancer Therapeutics*, **2017**, 117-137	0.3	1
17	FGFR signaling maintains a drug persistent cell population following epithelial-mesenchymal transition. *Oncotarget*, **2016**, 7, 83424-83436	3.3	36
16	Covalent Targeting of Fibroblast Growth Factor Receptor Inhibits Metastatic Breast Cancer. *Molecular Cancer Therapeutics*, **2016**, 15, 2096-106	6.1	51
15	Deptor enhances triple-negative breast cancer metastasis and chemoresistance through coupling to survivin expression. *Neoplasia*, **2015**, 17, 317-28	6.4	33
14	The antitumorigenic function of EGFR in metastatic breast cancer is regulated by expression of Mig6. *Neoplasia*, **2015**, 17, 124-33	6.4	26
13	Fibroblast growth factor receptor splice variants are stable markers of oncogenic transforming growth factor signaling in metastatic breast cancers. *Breast Cancer Research*, **2014**, 16, R24	8.3	41
12	STAT3 and epithelial-mesenchymal transitions in carcinomas. *Jak-stat*, **2014**, 3, e28975		120
11	Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway. *Journal of Biological Chemistry*, **2013**, 288, 17954-67	5.4	102
10	Deconstructing the mechanisms and consequences of TGF- induced EMT during cancer progression. *Cell and Tissue Research*, **2012**, 347, 85-101	4.2	171
9	Down-regulation of epithelial cadherin is required to initiate metastatic outgrowth of breast cancer. *Molecular Biology of the Cell*, **2011**, 22, 2423-35	3.5	130
8	integrin-EGF receptor cross-talk activates p190RhoGAP in mouse mammary gland epithelial cells. *Molecular Biology of the Cell*, **2011**, 22, 4288-301	3.5	28

7	p130Cas is required for mammary tumor growth and transforming growth factor-beta-mediated metastasis through regulation of Smad2/3 activity. *Journal of Biological Chemistry*, **2009**, 284, 34145-56	5.4	58
6	Mechanisms of the epithelial-mesenchymal transition by TGF-beta. *Future Oncology*, **2009**, 5, 1145-68	3.6	238
5	Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis. *Breast Cancer Research*, **2009**, 11, R68	8.3	127
4	Pyruvate carboxylase supports the pulmonary tropism of metastatic breast cancer		3
3	Transglutaminase-2 facilitates extracellular vesicle-mediated establishment of the metastatic niche		3
2	Biased signaling downstream of epidermal growth factor receptor regulates proliferative versus apoptotic response to ligand		1
1	Fibroblast growth factor receptor facilitates recurrence of minimal residual disease following trastuzumab emtansine therapy		2